Biocon mylan

Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association’s...

Bengaluru, Karnataka, India and HERTFORDSHIRE, England, PITTSBURGH, June 10/11, 2017 – Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced the presentation of new data from the insulin...
biocon academy website screenshot

Biocon Academy Introduces First Of Its Kind Career Advancement Program In ‘Clinical Development’ in...

Bengaluru, Karnataka, India, June 08, 2017: Biocon Academy, a CSR initiative of Asia’s leading biotechnology company, has announced the introduction of a unique program in ‘Clinical Development’ in collaboration with Keck Graduate Institute (KGI) in...
Vaxon biotech

Vaxon announces results of its Phase IIb lung cancer trial of Vx-001

Paris, France, June 1, 2017 – Vaxon, a biopharmaceutical company developing therapeutic cancer vaccines based on optimized cryptic peptides, announces the results of its Phase IIb trial of Vx-001 in non-small-cell lung cancer (NSCLC)....
imcyse

Imcyse obtains authorization to launch Phase 1b trial in Type 1 diabetes

Liège, Belgium, May 30, 2017 – Imcyse, who develop active specific therapies for the treatment and prevention of severe chronic diseases, today announces that the Belgian and British regulatory authorities have authorized the launch...
medicen

Medicen Paris Region announces 20% business growth in 2016

Paris, May 18, 2017 – Medicen Paris Region, Europe’s leading healthcare cluster, today announces its review of business for the previous year. The 20% growth in activity was reflected in the budget increase, from...
Robocath

Robocath raises €4.7 million ($5.2M) to market its first medical robotic platform, R-one™, in...

Robocath, a medical robotics start-up that designs and develops innovative solutions for the treatment of cardiovascular diseases, today announces the conclusion of a new round of fundraising worth €4.7 million ($5.2M). This round was...
ATUM

ATUM Licenses Gene Design Software to Thermo Fisher Scientific

ATUM (formerly DNA2.0, Inc.) announced today that the company has signed a patent licensing agreement that gives Thermo Fisher Scientific access to the company’s novel gene design platform. "Most people think visually, so seeing a...
Orthonika

Orthonika accelerates development of total meniscus replacement and secures additional funding

Orthonika Limited, a spin-out from Imperial College London, is pleased to announce success in securing funding for development of its novel synthetic total knee meniscus replacement. The company has closed a second round of...
SynbiCITE BrisSynBio4

Two new start-up plans win BrisSynBio’s first synthetic biology entrepreneurship competition

London, UK, 11th May 2017 / Sciad Newswire / Two start-ups' proposals have been chosen as the winners of the first competition to discover and accelerate new synthetic biology companies at the University of Bristol. The...
Alexandre Carpentier CarThera SonoCloud

CarThera to present data from phase 1/2a study focusing on disrupting blood-brain barrier for...

Paris, France, May 10, 2017 – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, today announces that Dr. Ahmed Idbaih, AP-HP principal investigator of the Phase...